Allergy immunotherapy (AIT), also known as desensitization or hypo-sensitization, involves exposing people to gradually increasing doses of allergens to decrease the symptoms of hay fever and other allergic reactions. AIT helps treat pet dander, pollen, dust mites, and other allergies by altering the body's immune response and reducing sensitivity to these allergens.
Market key trends:
One of the major trends in the allergy immunotherapy market is the rise of sublingual immunotherapy (SLIT). SLIT involves tablets or liquid doses of an allergen that are held under the tongue until they dissolve. This offers a more convenient alternative to allergy shots. SLIT tablets are growing in popularity due to their ease of use at home and lower risk of anaphylaxis compared to injections. Manufacturers are focusing on developing advanced SLIT formulations to further drive their adoption.
Segment Analysis
The global allergy immunotherapy market is segmented into allergen types, route of administration and distribution channel. Based on allergen types, the market is categorized into pollen immunotherapy, dust mite immunotherapy, cockroach immunotherapy and others. The pollen immunotherapy segment dominates the global market as it offers treatment against seasonal allergies caused by pollen from trees, grasses, or weeds. According to research, pollen immunotherapy has shown highest efficacy in the treatment of allergies compared to other allergen types immunotherapy treatment.
The global Allergy Immunotherapy Market Share is estimated to be valued at US$ 2,116.0 Million in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights
Key Takeaway:
The global allergy immunotherapy market size is expected to reach US$ 4,349.1 million by 2030, expanding at a CAGR of 9.3% over the forecast period. Growing prevalence of allergies caused by pollen, dust and other allergens on account of changing climatic conditions and pollution levels is anticipated to drive the market during the forecast period.
Regional analysis considered most promising is North America. The region accounts for the largest share in the global market owing to increasing healthcare spending and rising incidence of allergies. Asia Pacific is expected to witness fastest growth over the forecast period owing to growing awareness regarding allergy immunotherapy treatment and improving healthcare facilities in countries such as China and India.
Key players operating in the allergy immunotherapy market are Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier. Key players are focusing on new product launches, collaborative agreements and geographical expansion to strengthen their global presence.
